Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma
Byoung-San Moon, … , Min Yu, Wange Lu
Byoung-San Moon, … , Min Yu, Wange Lu
Published October 5, 2020
Citation Information: J Clin Invest. 2020;130(11):5782-5799. https://doi.org/10.1172/JCI127916.
View: Text | PDF
Research Article Oncology

Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma

  • Text
  • PDF
Abstract

Glioblastoma multiforme (GBM) heterogeneity causes a greater number of deaths than any other brain tumor, despite the availability of alkylating chemotherapy. GBM stem-like cells (GSCs) contribute to GBM complexity and chemoresistance, but it remains challenging to identify and target GSCs or factors that control their activity. Here, we identified a specific GSC subset and show that activity of these cells is positively regulated by stabilization of methyl CpG binding domain 3 (MBD3) protein. MBD3 binds to CK1A and to BTRCP E3 ubiquitin ligase, triggering MBD3 degradation, suggesting that modulating this circuit could antagonize GBM recurrence. Accordingly, xenograft mice treated with the CK1A activator pyrvinium pamoate (Pyr-Pam) showed enhanced MBD3 degradation in cells expressing high levels of O6-methylguanine-DNA methyltransferase (MGMT) and in GSCs, overcoming temozolomide chemoresistance. Pyr-Pam blocked recruitment of MBD3 and the repressive nucleosome remodeling and deacetylase (NuRD) complex to neurogenesis-associated gene loci and increased acetyl–histone H3 activity and GSC differentiation. We conclude that CK1A/BTRCP/MBD3/NuRD signaling modulates GSC activation and malignancy, and that targeting this signaling could suppress GSC proliferation and GBM recurrence.

Authors

Byoung-San Moon, Mingyang Cai, Grace Lee, Tong Zhao, Xiaofeng Song, Steven L. Giannotta, Frank J. Attenello, Min Yu, Wange Lu

×

Figure 2

Degradation and ubiquitination of MBD3 in GSCs.

Options: View larger image (or click on image) Download as PowerPoint
Degradation and ubiquitination of MBD3 in GSCs.
(A) Left: CD44+CD133+CXC...
(A) Left: CD44+CD133+CXCR4+ triple-positive cells sorted by FACS from T98G GSCs at a purity of 99.8% were grown on coverslips to monitor differentiation capacity over 5 days. Right: Undifferentiated cells (Un) and cells after 5 days of differentiation (D5) were analyzed by immunofluorescence with the indicated antibodies. Nuclei were counterstained with DAPI. Scale bars: 50 μm. (B) qPCR analysis of the indicated mRNAs in samples from A (n = 3 or 4). (C) Immunoblot (IB) analysis of MBD3 and α-tubulin in lysates of T98G GSCs, treated with cycloheximide (CHX) for indicated times (h, hours) and with or without MG132. (D) T98G GSCs were treated with MG132 for 0, 3, 6, and 9 hours before harvesting. Whole-cell lysates (WCLs) were immunoblotted using the indicated antibodies. (E and F) Ubiquitination assay of overexpressed or endogenous MBD3 using indicated lysates of cells transfected with MBD3-Flag and HA-Ub expression vectors and treated 1 day later with MG132 for 6 hours before harvesting. After lysis, immunoprecipitation (IP) was performed with Flag-M2 beads or MBD3 antibody. WCLs were analyzed by IB with the indicated antibodies. Data are presented as the mean ± SD. *P < 0.05; **P < 0.005; ***P < 0.0005 by unpaired, 2-tailed Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts